Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free FHTX Stock Alerts

Foghorn Therapeutics (FHTX) Competitors

Foghorn Therapeutics logo
$4.86 +0.25 (+5.42%)
Closing price 08/4/2026 04:00 PM Eastern
Extended Trading
$4.82 -0.04 (-0.82%)
As of 08:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

FHTX vs. INBX, CALT, ETON, IMTX, and COLL

Should you buy Foghorn Therapeutics stock or one of its competitors? MarketBeat compares Foghorn Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Foghorn Therapeutics include Inhibrx Biosciences (INBX), Calliditas Therapeutics AB (publ) (CALT), Eton Pharmaceuticals (ETON), Immatics (IMTX), and Collegium Pharmaceutical (COLL).

How does Foghorn Therapeutics compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Foghorn Therapeutics has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inhibrx Biosciences$1.30M949.78-$140.05M-$8.39N/A
Foghorn Therapeutics$30.91M9.23-$74.28M-$1.16N/A

Inhibrx Biosciences has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Inhibrx Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Inhibrx BiosciencesN/A -563.90% -72.32%
Foghorn Therapeutics -266.88%N/A -35.38%

Inhibrx Biosciences has a beta of 3.51, suggesting that its share price is 251% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, suggesting that its share price is 189% more volatile than the broader market.

In the previous week, Inhibrx Biosciences had 4 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 4 mentions for Inhibrx Biosciences and 0 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.96 beat Inhibrx Biosciences' score of 0.72 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Inhibrx Biosciences Positive
Foghorn Therapeutics Positive

Inhibrx Biosciences presently has a consensus price target of $150.00, indicating a potential upside of 78.22%. Foghorn Therapeutics has a consensus price target of $11.43, indicating a potential upside of 135.16%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Inhibrx Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibrx Biosciences
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.33
Foghorn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Foghorn Therapeutics beats Inhibrx Biosciences on 10 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Calliditas Therapeutics AB (publ)?

Foghorn Therapeutics (NASDAQ:FHTX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Foghorn Therapeutics has a beta of 2.89, indicating that its share price is 189% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Foghorn Therapeutics-266.88% N/A -35.38%
Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96%

In the previous week, Foghorn Therapeutics' average media sentiment score of 0.96 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Foghorn Therapeutics Positive
Calliditas Therapeutics AB (publ) Neutral

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Foghorn Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Foghorn Therapeutics$30.91M9.23-$74.28M-$1.16N/A
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A

Foghorn Therapeutics currently has a consensus price target of $11.43, indicating a potential upside of 135.16%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Foghorn Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Foghorn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Foghorn Therapeutics beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Eton Pharmaceuticals has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, meaning that its share price is 189% more volatile than the broader market.

Eton Pharmaceuticals has a net margin of -1.70% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Eton Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eton Pharmaceuticals-1.70% -5.68% -1.49%
Foghorn Therapeutics -266.88%N/A -35.38%

In the previous week, Eton Pharmaceuticals had 6 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 6 mentions for Eton Pharmaceuticals and 0 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.96 beat Eton Pharmaceuticals' score of 0.21 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Eton Pharmaceuticals Neutral
Foghorn Therapeutics Positive

Eton Pharmaceuticals presently has a consensus target price of $52.50, suggesting a potential upside of 14.55%. Foghorn Therapeutics has a consensus target price of $11.43, suggesting a potential upside of 135.16%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Eton Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eton Pharmaceuticals
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.50
Foghorn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Eton Pharmaceuticals has higher revenue and earnings than Foghorn Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eton Pharmaceuticals$79.95M15.70-$4.60M-$0.07N/A
Foghorn Therapeutics$30.91M9.23-$74.28M-$1.16N/A

Summary

Eton Pharmaceuticals and Foghorn Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Immatics?

Foghorn Therapeutics (NASDAQ:FHTX) and Immatics (NASDAQ:IMTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Foghorn Therapeutics has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Foghorn Therapeutics$30.91M9.23-$74.28M-$1.16N/A
Immatics$54.60M23.03-$222.26M-$1.99N/A

Foghorn Therapeutics presently has a consensus target price of $11.43, suggesting a potential upside of 135.16%. Immatics has a consensus target price of $20.80, suggesting a potential upside of 121.75%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Foghorn Therapeutics is more favorable than Immatics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Foghorn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
Immatics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

In the previous week, Immatics had 3 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for Immatics and 0 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.96 beat Immatics' score of 0.70 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Foghorn Therapeutics Positive
Immatics Positive

Foghorn Therapeutics has a net margin of -266.88% compared to Immatics' net margin of -572.35%. Foghorn Therapeutics' return on equity of 0.00% beat Immatics' return on equity.

Company Net Margins Return on Equity Return on Assets
Foghorn Therapeutics-266.88% N/A -35.38%
Immatics -572.35%-47.36%-39.35%

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Foghorn Therapeutics has a beta of 2.89, suggesting that its share price is 189% more volatile than the broader market. Comparatively, Immatics has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

Summary

Foghorn Therapeutics beats Immatics on 12 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Collegium Pharmaceutical has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, suggesting that its stock price is 189% more volatile than the broader market.

61.6% of Foghorn Therapeutics shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Collegium Pharmaceutical currently has a consensus target price of $57.50, suggesting a potential upside of 60.93%. Foghorn Therapeutics has a consensus target price of $11.43, suggesting a potential upside of 135.16%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than Collegium Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Collegium Pharmaceutical
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.83
Foghorn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

In the previous week, Collegium Pharmaceutical had 8 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 8 mentions for Collegium Pharmaceutical and 0 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.96 beat Collegium Pharmaceutical's score of 0.45 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Collegium Pharmaceutical Neutral
Foghorn Therapeutics Positive

Collegium Pharmaceutical has a net margin of 9.41% compared to Foghorn Therapeutics' net margin of -266.88%. Collegium Pharmaceutical's return on equity of 95.18% beat Foghorn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Collegium Pharmaceutical9.41% 95.18% 16.39%
Foghorn Therapeutics -266.88%N/A -35.38%

Collegium Pharmaceutical has higher revenue and earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collegium Pharmaceutical$780.57M1.48$62.87M$2.0417.51
Foghorn Therapeutics$30.91M9.23-$74.28M-$1.16N/A

Summary

Collegium Pharmaceutical and Foghorn Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Foghorn Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FHTX vs. The Competition

Export
MetricFoghorn TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$270.67M$3.52B$6.83B$12.77B
Dividend YieldN/A3.77%2.60%10.01%
P/E Ratio-4.197.32279.1525.53
Price / Sales9.231,279.23591.0092.31
Price / CashN/A103.4472.1149.39
Price / Book-2.5317.2513.026.11
Net Income-$74.28M-$12.52M$3.48B$347.58M
7 Day Performance2.53%3.63%3.39%4.91%
1 Month Performance-8.30%-5.38%-2.80%-2.06%
1 Year Performance-2.80%49.44%73.07%21.03%

Foghorn Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FHTX
Foghorn Therapeutics
3.3075 of 5 stars		$4.86
+5.4%		$11.43
+135.2%		-5.4%$270.67M$30.91MN/A120
INBX
Inhibrx Biosciences
2.4919 of 5 stars		$79.68
-3.4%		$150.00
+88.3%		+286.1%$1.21B$1.30MN/A166
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat		N/AN/A$1.19B$1.60BN/A180
ETON
Eton Pharmaceuticals
3.8684 of 5 stars		$46.66
+10.3%		$52.50
+12.5%		+218.5%$1.16B$79.95MN/A20
IMTX
Immatics
2.3382 of 5 stars		$8.73
+1.2%		$20.80
+138.3%		+41.9%$1.16B$54.60MN/A260

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:FHTX) was last updated on 8/5/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel